Atorvastatin’in amikasin kaynaklı ototoksisiteye karşı koruyucu etkisi: Sıçanlarda deneysel bir çalışma

Öz

Amaç: Amikasin gibi aminoglikozid antibiyotikler, ototoksisite nedeniyle geri dönüşümsüz işitme kaybına neden olabilir. Bu çalışma, sıçan modelinde atorvastatinin amikasin kaynaklı ototoksisiteye karşı potansiyel koruyucu etkilerini araştırmayı amaçlamıştır. Gereç ve Yöntemler: Yirmi Wistar Albino sıçan dört gruba ayrıldı: kontrol, atorvastatin (10 mg/kg/gün), amikasin (600 mg/kg/gün) ve amikasin + statinler. İşitsel fonksiyon, 0., 7. ve 14. günlerde İşitsel Beyin Sapı Yanıtı (ABR) ve Distorsiyon Ürün Otoakustik Emisyon (DPOAE) testleri kullanılarak değerlendirildi. Bulgular: Amikasin grubu, başlangıç değerine kıyasla 7. ve 14. günlerde önemli ölçüde işitme kaybı gösterirken (p < 0,001), amikasin + statin grubu, amikasin grubuna kıyasla önemli ölçüde daha iyi işitme eşiklerine sahipti (p < 0,001). DPOAE değerleri, amikasin ve amikasin + statin gruplarında, özellikle 7. ve 14. günlerde yüksek frekanslarda (4000-6000 Hz) önemli ölçüde azaldı (p < 0,001). Ancak, bu azalma amikasin + statin grubunda daha az belirgindi. Kontrol veya statin gruplarında işitmede önemli bir değişiklik gözlenmedi. Sonuç: Bu bulgular, atorvastatinin muhtemelen antioksidan ve antienflamatuar özellikleri sayesinde amikasin kaynaklı ototoksisiteyi azaltabileceğini düşündürmektedir. Bu sonuçların klinik geçerliliğini doğrulamak ve aminoglikozid tedavisiyle ilişkili işitme kaybı riskini azaltmak için yeni bir strateji olarak atorvastatinin potansiyelini araştırmak için daha fazla araştırma yapılması gerekmektedir.

Anahtar Kelimeler

• Amikasin
• atorvastatin
• Distorsiyon Ürünü Otoakustik Emisyon (DPOAE)
• İşitsel Beyin Sapı Yanıtı (ABR)
• ototoksisite

Destekleyen Kurum

yok

Proje Numarası

none

Etik Beyan

Bu deneysel çalışma, Sağlık Bilimleri Üniversitesi (SBÜ) Ankara Eğitim ve Araştırma Hastanesi Hayvan Deneyleri Yerel Etik Kurulu tarafından onaylanmıştır (tarih: 31.05.2018; onay no: 0046). Tüm işlemler, Helsinki Bildirgesi ve Deneysel ve Diğer Bilimsel Amaçlarla Kullanılan Omurgalı Hayvanların Korunmasına Dair Avrupa Sözleşmesi’ne (ETS 123) uygun olarak gerçekleştirilmiştir.

Teşekkür

yok

Atorvastatin's protective effect against amikacin-induced ototoxicity: An experimental study in rats

Öz

Aim: Aminoglycoside antibiotics such as amikacin can cause irreversible hearing loss due to ototoxicity. This study aimed to investigate the potential protective effects of atorvastatin against amikacin-induced ototoxicity in a rat model. Material and Methods: Twenty Wistar Albino rats were divided into four groups: control, atorvastatin (10 mg/kg/day), amikacin (600 mg/kg/day), and amikacin + statins. Auditory function was evaluated using Auditory Brainstem Response (ABR) and Distortion Product Otoacoustic Emission (DPOAE) tests on days 0, 7, and 14. Results: The amikacin group showed significant hearing loss on days 7 and 14 compared with baseline (p < 0.001), whereas the amikacin + statin group had significantly better hearing thresholds than the amikacin group (p < 0.001). The DPOAE values decreased significantly in the amikacin and amikacin + statin groups, especially at high frequencies (4000-6000 Hz) on days 7 and 14 (p < 0.001). However, this decrease was less pronounced in the amikacin + statin group. No significant changes in hearing were observed in the control or statin groups. Conclusion: These findings suggest that atorvastatin may attenuate amikacin-induced ototoxicity, possibly through its antioxidant and anti-inflammatory properties. Further well-designed studies are required to confirm the clinical relevance of these results and to explore the potential of atorvastatin as a strategy to reduce the risk of hearing loss associated with aminoglycoside therapy.

Anahtar Kelimeler

• Amikacin
• atorvastatin
• Auditory Brainstem Response (ABR)
• Distortion Product Otoacoustic Emission (DPOAE)
• ototoxicity

Destekleyen Kurum

none

Proje Numarası

none

Etik Beyan

This experimental study was approved by the Local Ethics Committee for Animal Experiments of the University of Health Sciences (SBU) Ankara Training and Research Hospital (date: 31.05.2018; approval number: 0046). All procedures were conducted in accordance with the Declaration of Helsinki and the European Convention on the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (ETS 123).

Teşekkür

none

Kaynakça

1. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119-126. https://doi.org/10.2174/138161207779313731
2. Dillard LK, Martinez RX, Perez LL, Fullerton AM, Chadha S, McMahon CM. Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review. J Infect. 2021;83(1):27-36. https://doi.org/10.1016/j.jinf.2021.05.010
3. Gaffney PJ, Shetty KR, Yuksel S, Kaul VF. Antioxidant therapies in the treatment of aminoglycoside-induced ototoxicity: a meta-analysis. Laryngoscope. 2025;135(4):1278-1286. https://doi.org/10.1002/lary.31902
4. Liu S, Zhang X, Sun M, Xu T, Wang A. FoxO3a plays a key role in the protective effects of pomegranate peel extract against amikacin-induced ototoxicity. Int J Mol Med. 2017;40(1):175-181. https://doi.org/10.3892/ijmm.2017.3003
5. Fernandez KA, Allen P, Campbell M, Page B, Townes T, Li CM, et al. Atorvastatin is associated with reduced cisplatin-induced hearing loss. J Clin Invest. 2021;131(1):e142616. https://doi.org/10.1172/JCI142616
6. Fernandez K, Spielbauer KK, Rusheen A, Wang L, Baker TG, Eyles S, et al. Lovastatin protects against cisplatin-induced hearing loss in mice. Hear Res. 2020;389:107905. https://doi.org/10.1016/j.heares.2020.107905
7. Kim YR, Kwon TJ, Kim UK, Lee IK, Lee KY, Baek JI. Fursultiamine prevents drug-induced ototoxicity by reducing accumulation of reactive oxygen species in mouse cochlea. Antioxidants (Basel). 2021;10(10):1526. https://doi.org/10.3390/antiox10101526
8. Kim YR, Kim MA, Cho HJ, Oh SK, Lee IK, Kim UK, et al. Galangin prevents aminoglycoside-induced ototoxicity by decreasing mitochondrial production of reactive oxygen species in mouse cochlear cultures. Toxicol Lett. 2016;245:78-85. https://doi.org/10.1016/j.toxlet.2016.01.005

9. Prokhorova I, Altman RB, Djumagulov M, Shrestha JP, Urzhumtsev A, Ferguson A, et al. Aminoglycoside interactions and impacts on the eukaryotic ribosome. Proc Natl Acad Sci U S A. 2017;114(51):E10899-E10908. https://doi.org/10.1073/pnas.1715501114
10. Kim YR, Baek JI, Lee KY, Kim UK. Berberine chloride protects cochlear hair cells from aminoglycoside-induced ototoxicity by reducing the accumulation of mitochondrial reactive oxygen species. Free Radic Biol Med. 2023;204:177-183. https://doi.org/10.1016/j.freeradbiomed.2023.04.017
11. Sagwa EL, Souverein PC, Ribeiro I, Leufkens HG, Mantel-Teeuwisse AK. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment. Pharmacoepidemiol Drug Saf. 2017;26(1):1-8. https://doi.org/10.1002/pds.4125
12. Aksoy F, Dogan R, Ozturan O, Eren SB, Veyseller B, Pektas A, et al. Protective effect of trimetazidine on amikacin-induced ototoxicity in rats. Int J Pediatr Otorhinolaryngol. 2014;78(4):663-669. https://doi.org/10.1016/j.ijporl.2014.01.031
13. Apaydın E, Dağlı E, Bayrak S, Kankılıç ES, Şahin H, Acar A. Protective effect of creatine on amikacin-induced ototoxicity. Braz J Otorhinolaryngol. 2022;88(5):651-656. https://doi.org/10.1016/j.bjorl.2020.09.002
14. Dedeoğlu S, Ayral M. Protective effect of ethyl pyruvate on amikacin-induced ototoxicity in rats. Eur Rev Med Pharmacol Sci. 2022;26(7):2460-2466. https://doi.org/10.26355/eurrev_202204_28480
15. Fernandez K, Wafa T, Fitzgerald TS, Cunningham LL. An optimized, clinically relevant mouse model of cisplatin-induced ototoxicity. Hear Res. 2019;375:66-74. https://doi.org/10.1016/j.heares.2019.02.006
16. Pasdelou MP, Byelyayeva L, Malmström S, Pucheu S, Peytavy M, Laullier H, et al. Ototoxicity: a high risk to auditory function that needs to be monitored in drug development. Front Mol Neurosci. 2024;17:1379743. https://doi.org/10.3389/fnmol.2024.1379743
17. Avcı D, Erkan M, Sönmez MF, Kökoğlu K, Güneş MS, Gündoğdu R, et al. A prospective experimental study on the protective effect of resveratrol against amikacin-induced ototoxicity in rats. J Int Adv Otol. 2016;12(3):290-297. https://doi.org/10.5152/iao.2016.2617
18. El-Anwar MW, Abdelmonem S, Nada E, Galhoom D, Abdelsameea AA. Protective effect of pentoxifylline on amikacin-induced ototoxicity. Ear Nose Throat J. 2018;97(8):E8-E12. https://doi.org/10.1177/014556131809700802
19. Zadrozniak M, Szymanski M, Luszczki JJ. Vitamin C alleviates ototoxic effect caused by coadministration of amikacin and furosemide. Pharmacol Rep. 2019;71(2):351-356. https://doi.org/10.1016/j.pharep.2019.01.002
20. Zadrożniak M, Szymański M, Łuszczki JJ. N-Acetyl-L-cysteine affects ototoxicity evoked by amikacin and furosemide either alone or in combination in a mouse model of hearing threshold decrease. Int J Mol Sci. 2023;24(8):7596. https://doi.org/10.3390/ijms24087596
21. El-Anwar MW, Abdelmonem S, Nada E, Galhoom D, Abdelsameea AA. Cilostazol effect on amikacin-induced ototoxicity: an experimental study. Audiol Neurootol. 2016;21(4):250-253. https://doi.org/10.1159/000446467
22. Kitcher SR, Kirkwood NK, Camci ED, Wu P, Gibson RM, Redila VA, et al. ORC-13661 protects sensory hair cells from aminoglycoside and cisplatin ototoxicity. JCI Insight. 2019;4(15):e126764. https://doi.org/10.1172/jci.insight.126764
23. Brand Y, Setz C, Levano S, Listyo A, Chavez E, Pak K, et al. Simvastatin protects auditory hair cells from gentamicin-induced toxicity and activates Akt signaling in vitro. BMC Neurosci. 2011;12:114. https://doi.org/10.1186/1471-2202-12-114
24. Lee CH, Jeon J, Lee SM, Kim SY. Pravastatin administration alleviates kanamycin-induced cochlear injury and hearing loss. Int J Mol Sci. 2022;23(9):4524. https://doi.org/10.3390/ijms23094524
25. Jahani L, Mehrparvar AH, Esmailidehaj M, Rezvani ME, Moghbelolhossein B, Razmjooei Z. The effect of atorvastatin on preventing noise-induced hearing loss: an experimental study. Int J Occup Environ Med. 2016;7(1):15-21. https://doi.org/10.15171/ijoem.2016.627